Ivabradin Krka

Ivabradine, the active ingredient in Ivabradin Krka, is an If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and in heart failure with reduced ejection fraction. The medication is indicated for patients who require heart‑rate reduction without a decrease in myocardial contractility.

GNH USA supplies Ivabradin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance.

Ivabradine acts on the cardiac pacemaker If current, making it useful in conditions where heart‑rate reduction improves symptoms and outcomes. - Chronic stable angina: reduces heart rate, improving myocardial oxygen balance and decreasing angina episodes. - Heart failure with reduced ejection fraction: lowers heart rate, contributing to improved ventricular filling and clinical outcomes. - Symptomatic tachycardia in angina patients: decreases excessive heart rate, helping relieve chest discomfort during activity.

Ivabradine may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 beats/min. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: especially on standing. - Fatigue: general feeling of tiredness. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia: symptomatic, may require intervention. - Atrial fibrillation: new‑onset arrhythmia. - Symptomatic hypotension: marked blood pressure drop. - Visual loss: persistent visual impairment. - Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Ivabradine, clinicians should consider several safety measures to minimise risk and ensure appropriate use. - Cardiac monitoring: assess baseline heart rate and ECG before initiation. - Concomitant beta‑blockers: avoid excessive heart‑rate reduction by adjusting doses. - Severe hepatic impairment: use with caution due to altered metabolism. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradine can interact with other medicines that affect its metabolism or heart‑rate control, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce efficacy. - Other If‑channel inhibitors: additive bradycardic effect.

Moderate Interactions (Monitor Closely): - Calcium‑channel blockers (verapamil, diltiazem): may enhance bradycardia. - Digoxin: potential for increased arrhythmic risk. - Antihypertensive agents: monitor blood pressure and heart rate.